Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2023-05-26 Director's Dealing
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details a transaction (Acquisition) by 'Prof. Dr. Andreas Pahl', who is a 'Member of the managing body' of Heidelberg Pharma AG. This content directly matches the definition for Director's Dealing.
2023-05-26 English
Heidelberg Pharma reports on the results of the Annual General Meeting 2023
AGM Information Classification · 99% confidence The document explicitly states in the title and body: "Heidelberg Pharma reports on the results of the Annual General Meeting 2023". It details the resolutions approved by shareholders during the meeting (e.g., discharge of board members, election of a new member, approval of remuneration report). This content directly corresponds to the reporting of outcomes from an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information). The document is a press release announcing the results, not the formal voting results document (DVA) or the proxy materials (PSI).
2023-05-25 English
Heidelberg Pharma appoints Chief Financial Officer
Board/Management Information Classification · 100% confidence The document is a press release dated May 5, 2023, announcing the appointment of Walter Miller as the new Chief Financial Officer (CFO) of Heidelberg Pharma AG, effective May 1, 2023. This announcement details a change in senior management personnel. According to the definitions, announcements regarding changes in the company's board of directors or senior management fall under the 'Board/Management Information' category, which corresponds to the code MANG.
2023-05-05 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights'. It details a 'Conditional capital increase' and provides the 'New total number of voting rights' (46,597,597). This type of announcement, specifically detailing changes related to voting rights or capital structure changes that affect voting rights, aligns best with the 'Share Issue/Capital Change' (SHA) category, as a conditional capital increase is a capital structure change. While it relates to voting rights, it is not a DVA (Declaration of Voting Results) which concerns the outcome of a vote, nor is it a general regulatory filing (RNS). The content is a direct notification of a capital structure event affecting shareholder rights.
2023-04-28 English
Q1 statement / Q1 financial report 2022/2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Management Statement on the First Three Months of 2023' for Heidelberg Pharma AG. It contains detailed financial statements, including a balance sheet, income statement, and cash flow statement for the period ending February 28, 2023. It provides a comprehensive analysis of the company's financial position, operational developments, and outlook. Although it mentions that the full figures can be downloaded from their website, the document itself contains the substantive financial data and analysis required for an interim report, thus qualifying as an Interim/Quarterly Report (IR) rather than a mere announcement. Q1 2023
2023-04-19 English
Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25.05.2023 in Ladenburg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 100% confidence The document is explicitly titled "Bekanntmachung der Einberufung zur Hauptversammlung" (Announcement of the Convocation to the General Meeting) and contains an "Einladung zur ordentlichen virtuellen Hauptversammlung" (Invitation to the ordinary virtual General Meeting). It details the date (May 25, 2023), location (Ladenburg), agenda items (including approval of financial statements, discharge of management/supervisory boards, auditor appointment, election to the supervisory board, and changes to the articles of association regarding virtual meetings), and voting procedures. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2023-04-13 German

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.